The immunogenicity of human and murine cytomegaloviruses

Current Opinion in Immunology

Volumn 12, Issue 4, 2000, Pages 390-396

  Reddehase, Matthias J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN;

ANTIGEN PRESENTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EVOLUTION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; NONHUMAN; REVIEW; SPECIES DIFFERENCE; VIRUS GENE; VIRUS LATENCY;

EID: 0034131201     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00106-0     Document Type: Review

References (41)

1. Reddehase M.J., Weiland F., Münch K., Bühring H-J., Koszinowski U.H. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol. 55:1985;264-273.
2. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science. 257:1992;238-241.
3. Steffens H-P., Kurz S., Holtappels R., Reddehase M.J. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genome, and reduces the risk of virus recurrence. J Virol. 72:1998;1797-1804.
4. Polic B., Hengel H., Krmpotic A., Trgovcich J., Pavic I., Lucin P., Jonjic S., Koszinowski U.H. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med. 188:1998;1047-1054.
5. Reddehase M.J., Koszinowski U.H. Significance of herpes virus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature. 312:1984;369-371.
6. Reddehase M.J., Rothbard J.B., Koszinowski U.H. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature. 337:1989;651-653.
7. Borysiewicz L.K., Hickling J.K., Graham S., Sinclair J., Cranage M.P., Smith G.L., Sissons J.G.P. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med. 168:1988;919-931.
8. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., Sissons J.G.P. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 70:1996;7569-7579.
9. McLaughlin-Taylor E., Pande H., Forman S.J., Tanamachi B., Li C.R., Zaia J.A., Greenberg P.D., Riddell S.R. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol. 43:1994;103-110.
10. Reimann J., Schirmbeck R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol Rev. 172:1999;131-152.
11. Hengel H., Brune W., Koszinowski U.H. Immune evasion by cytomegalovirus - survival strategies of a highly adapted opportunist. Trends Microbiol. 6:1998;190-197.
12. Gilbert M.J., Riddell S.R., Plachter B., Greenberg P.D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 383:1996;720-722.
13. Holtappels R., Podlech J., Geginat G., Steffens H-P., Thomas D., Reddehase M.J. Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates. J Virol. 72:1998;7201-7212.
14. Gavin M.A., Gilbert M.J., Riddell S.R., Greenberg P.D., Bevan M.J. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol. 151:1993;3971-3980.
15. + T cells, previously thought to represent naive CTL precursors.
16. + T cells comprise both naive and memory cells. J Immunol. 162:1999;7080-7087.
17. Gyulai Z., Endresz V., Burian K., Pincus S., Toldi J., Cox W.I., Meric C., Plotkin S., Gönczöl E., Berencsi K. Cytotoxic T lymphocyte responses to HCMV pp65, IE1-exon4, gB, pp150, and pp28 in healthy individuals: re-evaluation of prevalence of IE1-specific CTL. J Infect Dis. 181:2000;1537-1546. A classical but careful and unbiased limiting dilution analysis of the prevalence and frequency of hCMV-specific CTLs in healthy donors, based on T cell re-stimulation with canarypox recombinants in place of DB-rich hCMV preparations.
18. +T cells.
19. Topilko A., Michelson S. Morphological and cytochemical analysis of human cytomegalovirus inoculum: correlation of free particles in inoculum with counterparts in infected cells. Res Virol. 145:1994;65-73.
20. Irmiere A., Gibson W. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology. 130:1983;118-133.
21. Klages S., Rüger B., Jahn G. Multiplicity dependent expression of the predominant phosphoprotein pp65 of human cytomegalovirus. Virus Res. 12:1989;159-168.
22. Reddehase M.J., Keil G.M., Koszinowski U.H. The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol. 14:1984;56-61.
23. Weiland F., Keil G.M., Reddehase M.J., Koszinowski U.H. Studies on the morphogenesis of murine cytomegalovirus. Intervirology. 26:1986;192-201.
24. Morello C.S., Cranmer L.D., Spector D.H. In vivo replication, latency, and immunogenicity of murine cytomegalovirus mutants with deletions in the M83 and M84 genes, the putative homologs of human cytomegalovirus pp65 (UL83). J Virol. 73:1999;7678-7693. The first study that addresses the immunological role of M83 and M84, the mCMV homologs of hCMV UL83.
25. Dechanet J., Merville P., Lim A., Retiere C., Pitard V., Lafarge X., Michelson S., Meric C., Hallet M.M., Kourilsky P.et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J Clin Invest. 103:1999;1437-1449.
26. Tomazin R., Boname J., Hegde N.R., Lewinsohn D.M., Altschuler Y., Jones T.R., Cresswell P., Nelson J.A., Riddell S.R., Johnson D.C. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med. 5:1999;1039-1043. Outstanding in that the work identifies the viral and cellular molecular partners involved in interference of hCMV with the MHC-II pathway of antigen presentation.
27. Le-Roy E., Muhlethaler-Mottet A., Davrinche C., Mach B., Davignon J.L. Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. J Virol. 73:1999;6582-6589.
28. Redpath S., Angulo A., Gascoigne N.R., Ghazal P. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J Immunol. 162:1999;6701-6707.
29. Huard B., Früh K. A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. Eur J Immunol. 30:2000;509-515. US11 of hCMV was shown previously to cause degradation of MHC-I molecules but other proteins of hCMV also induce downregulation of surface MHC-I that could trigger lysis by NK cells. The work demonstrates that US11 is sufficient to mediate both effects.
30. Farrell H.E., Degli-Esposti M.A., Davis-Poynter N.J. Cytomegalovirus evasion of natural killer cell responses. Immunol Rev. 168:1999;187-197.
31. +T cells, glycoprotein UL40 upregulates the nonclassical class-I molecule HLA-E to simultaneously silence NK cells.
32. Hengel H., Reusch U., Gutermann A., Ziegler H., Jonjic S., Lucin P., Koszinowski U.H. Cytomegaloviral control of MHC class I function in the mouse. Immunol Rev. 168:1999;167-176.
33. Reusch U., Muranyi W., Lucin P., Burgert H.G., Hengel H., Koszinowski U.H. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 18:1999;1081-1091. Very solid work identifying a further immunosubversive protein of mCMV, namely gp48 encoded by gene m06 (see also Figure 1d).
34. +T cell dependent attenuation of a Δm152 deletion mutant. The work thus provides the first evidence for in vivo relevance of an immunosubversive mechanism of a CMV.
35. Reddehase M.J., Fibi M.R., Keil G.M., Koszinowski U.H. Late-phase expression of a murine cytomegalovirus immediate-early antigen recognized by cytolytic T lymphocytes. J Virol. 60:1986;1125-1129.
36. Holtappels R., Thomas D., Podlech J., Geginat G., Steffens H-P., Reddehase M.J. The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells. J Virol. 74:2000;1871-1884. The work points to a likely future direction of CMV immunology. It describes the identification of the first antigenic CMV peptide that is derived from an E-phase protein and that apparently escapes the redundant immunosubversive mechanisms that affect the MHC-I pathway of antigen presentation during the E phase. Notably, the peptide is derived from m04/gp34 [37], a viral glycoprotein that may help to silence NK cells by directing MHC-I molecules to the cell surface (see also Figure 1d).
37. Kleijnen M.F., Huppa J.B., Lucin P., Mukherjee S., Farrell H., Campbell A.E., Koszinowski U.H., Hill A.B., Ploegh H.L. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 16:1997;685-694.
38. Solache A., Morgan C.L., Dodi A.I., Morte C., Scott I., Baboonian C., Zal B., Goldman J., Grundy J.E., Madrigal J.A. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol. 163:1999;5512-5518.
39. Retiere C., Prod'homme V., Imbert-Marcille B.M., Bonneville M., Vie H., Hallet M.M. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J Virol. 74:2000;3948-3952. In this recent work, several new antigenic peptides were identified for hCMV (see Table 1). Notably, the majority of CTL clones were found to be specific for peptides derived from polymorphic regions of the IE1 protein, indicating that IE1 is a target of immunological selection. The work thus further underscores our new view regarding the relevance of the hCMV IE1 protein for immune control, a relevance that has been experimentally proven for the IE1 protein of mCMV for a long time.
40. Kern F., Surel I.P., Brock C., Freistedt B., Radtke H., Scheffold A., Blasczyk R., Reinke P., Schneider-Mergener J., Radbruch A.et al. T-cell epitope mapping by flow cytometry. Nat Med. 4:1998;975-978.
41. Diamond D.J., York J., Sun J.Y., Wright C.L., Forman S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 90:1997;1751-1767.